NCT07843264
PPI Dosing Per CYP2C19 Genotype
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Notable Recruitment opened
- Start date changed from estimate of Oct 2026 to Nov 1, 2026
- Study sites: 0 to 1
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Improvement of Los Angeles (LA) classification of Erosive Esphagitis (EE) grade
Timeframe: 8 weeks
Arms and interventions
InterventionExperimental
proton pump inhibitor dose based on CYP2C19 phenotypes
ControlActive comparator
conventional proton pump inhibitor dose of Pantoprazole 40 mg once or twice daily
Drugs: CYP2C19 based dosing Proton Pump Inhibitors, Conventional proton pump inhibitor dose
Sites
1 site in 1 country
- UF HealthJacksonville, Florida, United States